Combining radiotherapy with immunotherapy – a review of past, present and future developments
New immunotherapy treatments are currently revolutionising the field of oncology [...]
Mixed results for nivolumab/ipilimumab combination in advanced kidney cancer
The results from the recent phase III CheckMate-214 clinical trial [...]
Initiation of a phase III trial of immunotherapy plus targeted therapy combinations versus sunitinib
Exelixis and Bristol-Myers Squibb have announced that they have initiated [...]
Combo immunotherapy doubles response rates and may herald a new standard of care
Results from a recent phase II study published in the [...]
Novel treatment options for kidney cancer presented at ASCO 2017
The following video is an interview between PracticeUpdate and Dr Bradley [...]
Promising clinical activities support combination immunotherapy for metastatic kidney cancer
The results of an open-label pilot study by researchers at [...]
Cabozantinib plus nivolumab phase 3 clinical trial in first-line kidney cancer
Exelixis and Bristol-Myers Squibb (BMS) have announced a clinical development [...]
Phase I study shows promise with nivolumab and ipilimumab combination in kidney cancer
Results from the CheckMate-016 study to investigate a combination of [...]
Nivolumab plus ipilimumab combo approved by NICE for melanoma
The National Institute for Health and Care Excellence (NICE) has [...]
Pfizer’s new cancer drug shows promise in combination with Merck’s Keytruda
Data from a small clinical trial were released last week [...]
